News
KALA
1.780
+2.89%
0.050
Weekly Report: what happened at KALA last week (0622-0626)?
Weekly Report · 3d ago
Weekly Report: what happened at KALA last week (0615-0619)?
Weekly Report · 06/22 10:10
Weekly Report: what happened at KALA last week (0608-0612)?
Weekly Report · 06/15 10:11
Weekly Report: what happened at KALA last week (0601-0605)?
Weekly Report · 06/08 10:07
Weekly Report: what happened at KALA last week (0525-0529)?
Weekly Report · 06/01 10:11
Weekly Report: what happened at KALA last week (0518-0522)?
Weekly Report · 05/25 10:14
Weekly Report: what happened at KALA last week (0511-0515)?
Weekly Report · 05/18 10:14
Kala Bio Q1 EPS $(0.14) Beats $(0.30) Estimate
Benzinga · 05/15 23:12
Kala Bio Q1 FY26 net loss narrows to $1.62 million
PUBT · 05/15 19:31
KALA BIO: Q1 Earnings Snapshot
Barchart · 05/15 14:36
Kala Bio falls -21.7%
TipRanks · 05/12 17:59
Weekly Report: what happened at KALA last week (0504-0508)?
Weekly Report · 05/11 10:11
Upcoming Stock Splits This Week (May 11 to May 15) – Stay Invested
TipRanks · 05/10 14:22
Kala Pharmaceuticals trading halted, news pending
TipRanks · 05/08 23:50
Kala Bio files $350M mixed securities shelf
TipRanks · 05/07 22:27
KALA BIO Implements 1-for-50 Reverse Stock Split
TipRanks · 05/07 21:32
KALA BIO INC - MAY OFFER UP TO $350 MLN IN SECURITIES - SEC FILING
Reuters · 05/07 21:26
Kala Bio announces reverse stock split
TipRanks · 05/07 18:28
Kala Bio Announces 1-For-50 Reverse Stock Split, Effective May 11
Benzinga · 05/07 13:03
*KALA BIO Intends to Effect Reverse Stk Split at Ratio of 1 Post-Split Shr for Every 50 Pre-Split Shrs >KALA
Dow Jones · 05/07 13:02
More
Webull provides a variety of real-time KALA stock news. You can receive the latest news about Kala Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.